DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin

References

• UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Perley M, Kipnis D. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest.46(12), 1954–1962 (1967).
   PubMed Web of Science ®Google Scholar
• Nauck M, Niedereichholz U, Ettler R. Reduced incretin effect in Type 2 diabetes. J. Clin. Endocrinol. Metab.63, 492–498 (1986).
   PubMed Web of Science ®Google Scholar
• Muller W, Faloona G, Aguilar-Parada E, Unger R. Abnormal α-cell function in diabetes: response to carbohydrate and protein ingestion. N. Engl. J. Med.2, 109–115 (1970).
   Google Scholar
• Saydah S, Fradkin J, Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J. Am. Med. Assoc.291(3), 335–342 (2004).
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen J, Holst J. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β-cell function in Type 2 diabetes: a parallel-group study. Lancet359, 824–830 (2002).
   PubMed Web of Science ®Google Scholar
• Stoffers D, Kieffer T, Hussain M. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes49, 741–748 (2000).
   PubMed Web of Science ®Google Scholar
• Xu G, Stoffers D, Habener J, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes48, 2270–2276 (1999).
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang X, Pineyro M, Egan J. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes48, 2358–2366 (1999).
   PubMed Web of Science ®Google Scholar
• Kendall D, Riddle M, Rosenstock J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care28, 1083–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Buse J, Henry R, Han J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care27, 2628–2635 (2004).
   PubMed Web of Science ®Google Scholar
• DeFronzo R, Ratner R, Han J. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care28, 1092–1100 (2005).
   PubMed Web of Science ®Google Scholar
• Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews D. Improved glycemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care27, 1335–1342 (2004).
   PubMed Web of Science ®Google Scholar
• Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin. Investig. Drugs15, 431–442 (2006).
   PubMed Web of Science ®Google Scholar
• Villhauer E, Brinkman J, Naderi G. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-S-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem.46, 2774–2789 (2003).
   PubMed Web of Science ®Google Scholar
• Mari A, Sallas W, He Y. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.90, 4888–4894 (2005).
   PubMed Web of Science ®Google Scholar
• Ahren B, Landin-Olsson M, Jansson P. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in Type 2 diabetes. J. Clin. Endocrinol. Metab.89, 2078–2084 (2004).
   PubMed Web of Science ®Google Scholar
• Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor, LAF237 improves glycemic control in patients with Type 2 diabetes (T2DM). Diabetes53(Suppl. 2), A83 (2004).
   Google Scholar
• Scherbaum WA et al. efficacy and tolerability of vildagliptin in drug-naïve patients with Type 2 diabetes (T2DM) and mild hyperglycemia. Presented at: American Diabetes Association, IL, USA, 22–26 June, 2007 (Poster 503).
   Google Scholar
• Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with Type 2 diabetes. Diabetes Care27, 2874–2880 (2004).
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Foley J, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with Type 2 diabetes over 1 year. Diabetes Care28, 1936–1940 (2005).
   PubMed Web of Science ®Google Scholar
• Garber AJ et al. Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with Type 2 diabetes (T2DM). Presented at: American Diabetes Association, IL, USA, 22–26 June, 2007 (Poster 501)
   Google Scholar
• Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care30(2), 217–223 (2007).
   PubMed Web of Science ®Google Scholar
• Dejager S, Lebeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1C during one-year treatment with vildagliptin in patients with Type 2 diabetes (T2DM). In: Program and abstracts of the American Diabetes Association 66th Scientific Sessions. Washington, DC, USA, 9–13 June, 2006.
   Google Scholar
• Matikainen N, Manttari S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type 2 diabetes. Diabetologia49, 2049–2057 (2006).
   PubMed Web of Science ®Google Scholar
• Garber A, Camisasca R, Ehrsam E. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with Type 2 diabetes (T2DM). In: Program and abstracts of the American Diabetes Association 66th Scientific Sessions. Washington, DC, USA, 9–13 June, 2006.
   Google Scholar
• Fonseca V, Schweizer A, Albrecht D, Baron M, Chang I. Addition of vildagliptin to insulin improves glycaemic control in Type 2 diabetes. Diabetologia50(6), 1148–1155 (2007).
   PubMed Web of Science ®Google Scholar
• Nathwani A, Lebeaut A, Syiers S, Gimpelewicz C, Chang I. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for Type 2 diabetes. In: Program and abstracts of the American Diabetes Association 66th Scientific Sessions. Washington, DC, USA, 9–13 June, 2006.
   Google Scholar
• Herman G, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin. Pharmacol. Ther.78(6), 675–688 (2005).
   PubMed Web of Science ®Google Scholar
• Scott R, Wu L, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with Type 2 diabetes. Int. J. Clin. Pract.61, 171–180 (2007).
   PubMed Web of Science ®Google Scholar
• Jago C. American Diabetes Association – 66th scientific sessions. IDrugs9, 538–541 (2006).
   PubMedGoogle Scholar
• Rosenstock J, Brazg R, Andryuk P, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with Type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther.28, 1556–1568 (2006).
   PubMed Web of Science ®Google Scholar